The market for obesity treatments is becoming increasingly competitive, with novartis and eli lilly emerging as key players. Some reports suggest eli lilly may be gaining an advantage, potentially widening the gap with its competitor, while others forecast significant growth in the market, with both companies expected to remain dominant. The outcome is uncertain, with some indications of novartis facing challenges, including a recent workforce reduction.